Hille Vax, Inc. HLVX
Institutional shares held
34.9 Million
0
calls
0
puts
Total value of holdings
$71.9M
$0
calls
$0
puts
Market Cap
$68.9M
33,427,200
Shares Out.
Institutional ownership
104.46%
# of Institutions
81
We take great care to ensure that the data presented and summarized in this overview for HilleVax, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HLVX
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$21.9 Million0.97% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$10.1 Million0.46% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$4.31 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$4.03 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.88 Million0.07% of portfolio
-
Abingworth LLP London, X01.84MShares$3.79 Million10.2% of portfolio
-
Carlyle Group Inc. Washington, DC1.84MShares$3.79 Million3.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.59MShares$3.27 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1MShares$2.07 Million0.0% of portfolio
-
Step Stone Group LP La Jolla, CA827KShares$1.7 Million3.48% of portfolio
Latest Institutional Activity in HLVX
Top Purchases
Top Sells
About HLVX
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Insider Transactions at HLVX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 23
2025
|
Patrick J Heron |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Aditya Kohli |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+2.4%
|
-
|
|
Jun 23
2025
|
Shelley Chu |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Jaime Sepulveda |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+22.51%
|
-
|
|
Jun 23
2025
|
Gary Dubin |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Julie L. Gerberding |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+22.51%
|
-
|
|
Jun 23
2025
|
Nanette Cocero |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+50.0%
|
-
|
|
Jun 23
2025
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
17,199
+22.51%
|
-
|
|
Feb 11
2025
|
Shane Maltbie Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,345
-5.16%
|
$4,345
$1.76 P/Share
|
|
Feb 11
2025
|
Robert Hershberg |
SELL
Open market or private sale
|
Direct |
11,901
-1.07%
|
$11,901
$1.76 P/Share
|
|
Feb 04
2025
|
Shane Maltbie Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,946
-4.48%
|
$3,946
$1.89 P/Share
|
|
Feb 04
2025
|
Robert Hershberg |
SELL
Open market or private sale
|
Direct |
14,634
-1.3%
|
$14,634
$1.89 P/Share
|
|
May 22
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.78%
|
$84,000
$14.73 P/Share
|
|
May 21
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.77%
|
$84,000
$14.21 P/Share
|
|
May 20
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.77%
|
$90,000
$15.45 P/Share
|
|
May 03
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
723
-0.09%
|
$10,122
$14.15 P/Share
|
|
May 02
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.76%
|
$84,000
$14.01 P/Share
|
|
May 01
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
175
-0.02%
|
$2,450
$14.03 P/Share
|
|
Apr 05
2024
|
Aditya Kohli |
SELL
Open market or private sale
|
Direct |
6,000
-0.75%
|
$84,000
$14.44 P/Share
|
|
Apr 04
2024
|
Frazier Life Sciences X, L.P. |
BUY
Open market or private purchase
|
Direct |
8,850
+0.1%
|
$123,900
$14.5 P/Share
|
Last 12 Months Summary
Buy / Acquisition
138K
Shares
From
8
Insiders
| Grant, award, or other acquisition | 138K shares |
|---|
Sell / Disposition
34.8K
Shares
From
2
Insiders
| Open market or private sale | 34.8K shares |
|---|